INS and Hypoglycemia: However, some investigators demonstrate that basal-bolus correction insulin regimen with glycemic target < 200 mg/dL in patients with ACS could lead to a hypoglycemic risk very close to zero (0.24%), with a significant reduction in hypoglycemia-related clinical events [51].